Oncology News | pharmaphorum

News

Merck & Co notches up another lung cancer use for Keytruda

Bristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its arch-rival, Merck & Co’s Keytruda in the indication.

News

Japan approves Roche's tumour agnostic cancer drug Rozlytrek

Japan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib).

News

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.

News

As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn

Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.

News

Roche's blockbuster breast cancer drug Herceptin

FDA approves Herceptin biosimilar as US patent expires

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen to develop Darzalex successor with Genmab

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth

Merck & Co notches up another lung cancer use for Keytruda

Japan approves Roche's tumour agnostic cancer drug Rozlytrek

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn

FDA approves Herceptin biosimilar as US patent expires

Janssen to develop Darzalex successor with Genmab

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks